HIV and Cardiovascular Disease: From Insights to Interventions

Matthew J. Feinstein*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Individuals with HIV have elevated risks for cardiovascular diseases (CVDs) ranging from myocardial infarction to heart failure. Our understanding of this heightened HIV-associated cardiovascular risk has evolved over the past 2 decades. In the early era of antiretroviral therapy (ART), concern existed that ART was the primary driver of cardiovascular risk. However, it has become increasingly apparent that HIV-related viremia, immune dysregulation, and inflammation are primary drivers of HIV-associated cardiovascular risk, along with traditional cardiovascular risk factors such as tobacco smoking. Indeed, early and effective ART blunts risk for CVDs among individuals with HIV. Despite these improvements in HIV-associated cardiovascular risk, questions remain regarding how to optimally predict, prevent, and treat CVDs among individuals with HIV. Efforts are underway to define more precisely which diagnostic and therapeutic strategies will be most effective in curbing HIV-associated CVDs.

Original languageEnglish (US)
Pages (from-to)407-411
Number of pages5
JournalTopics in antiviral medicine
Issue number4
StatePublished - Oct 1 2021


  • CVD
  • HIV
  • atherosclerosis
  • cardiovascular disease
  • heart failure
  • inflammation
  • myocardial infarction

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'HIV and Cardiovascular Disease: From Insights to Interventions'. Together they form a unique fingerprint.

Cite this